176 related articles for article (PubMed ID: 25042137)
1. Chapter 3: Molecular basis for the therapeutic effectiveness of botulinum neurotoxin type A.
Dolly JO; Lawrence GW
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S14-20. PubMed ID: 25042137
[TBL] [Abstract][Full Text] [Related]
2. Targets for botulinum toxin in the lower urinary tract.
Cruz F
Neurourol Urodyn; 2014 Jan; 33(1):31-8. PubMed ID: 23775898
[TBL] [Abstract][Full Text] [Related]
3. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
Nambiar A; Lucas M
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S21-5. PubMed ID: 25042139
[TBL] [Abstract][Full Text] [Related]
4. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
Cruz F; Nitti V
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders.
Lin YH; Chiang BJ; Liao CH
Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085522
[TBL] [Abstract][Full Text] [Related]
6. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity.
Apostolidis A; Popat R; Yiangou Y; Cockayne D; Ford AP; Davis JB; Dasgupta P; Fowler CJ; Anand P
J Urol; 2005 Sep; 174(3):977-82; discussion 982-3. PubMed ID: 16094018
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of action of botulinum neurotoxins, β3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011.
Kanai A; Zabbarova I; Oefelein M; Radziszewski P; Ikeda Y; Andersson KE
Neurourol Urodyn; 2012 Mar; 31(3):300-8. PubMed ID: 22275187
[TBL] [Abstract][Full Text] [Related]
8. Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014.
Apostolidis A; Rahnama'i MS; Fry C; Dmochowski R; Sahai A
Neurourol Urodyn; 2016 Feb; 35(2):293-8. PubMed ID: 26872570
[TBL] [Abstract][Full Text] [Related]
9. Effect of botulinum neurotoxin on the urinary bladder: novel insights on mechanism of action.
Vianello A; Proietti S; Giannantoni A
Minerva Urol Nefrol; 2010 Sep; 62(3):259-71. PubMed ID: 20940695
[TBL] [Abstract][Full Text] [Related]
10. Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium.
Hanna-Mitchell AT; Wolf-Johnston AS; Barrick SR; Kanai AJ; Chancellor MB; de Groat WC; Birder LA
Neurourol Urodyn; 2015 Jan; 34(1):79-84. PubMed ID: 24167028
[TBL] [Abstract][Full Text] [Related]
11. The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin.
Traini C; Vannucchi MG
Toxins (Basel); 2019 Oct; 11(11):. PubMed ID: 31652991
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury.
Smith CP; Gangitano DA; Munoz A; Salas NA; Boone TB; Aoki KR; Francis J; Somogyi GT
Neurochem Int; 2008 May; 52(6):1068-75. PubMed ID: 18187233
[TBL] [Abstract][Full Text] [Related]
13. Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome.
Liu HT; Chen SH; Chancellor MB; Kuo HC
PLoS One; 2015; 10(8):e0134803. PubMed ID: 26241848
[TBL] [Abstract][Full Text] [Related]
14. BoNT/A in the Urinary Bladder-More to the Story than Silencing of Cholinergic Nerves.
Ibrahim H; Maignel J; Hornby F; Daly D; Beard M
Toxins (Basel); 2022 Jan; 14(1):. PubMed ID: 35051030
[TBL] [Abstract][Full Text] [Related]
15. Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.
Wang J; Zurawski TH; Bodeker MO; Meng J; Boddul S; Aoki KR; Dolly JO
Biochem J; 2012 May; 444(1):59-67. PubMed ID: 22360156
[TBL] [Abstract][Full Text] [Related]
16. Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers.
Lawrence GW; Aoki KR; Dolly JO
J Pharmacol Exp Ther; 2010 Sep; 334(3):1080-6. PubMed ID: 20576797
[TBL] [Abstract][Full Text] [Related]
17. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
[TBL] [Abstract][Full Text] [Related]
18. Chapter 6: Practical aspects of administration of onabotulinumtoxinA.
Rovner E
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S32-7. PubMed ID: 25042141
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of muscarinic receptors in the urothelium and suburothelium of neurogenic and idiopathic overactive human bladders, and changes with botulinum neurotoxin administration.
Datta SN; Roosen A; Pullen A; Popat R; Rosenbaum TP; Elneil S; Dasgupta P; Fowler CJ; Apostolidis A
J Urol; 2010 Dec; 184(6):2578-85. PubMed ID: 21030043
[TBL] [Abstract][Full Text] [Related]
20. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
Tubaro A; Puccini F; De Nunzio C
Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
